

Address: 131 Great Western Highway
Blaxland 2774
D.O.B.: 27/01/1963
Record No.: 10772
Home Phone:
Work Phone:
Mobile Phone: 0414413627

Blaxland NSW 27
02470202

Printed on 13th May 2024

Investigations:

CARFAX-FOSTER, MARE HENRY
131 GREAT WESTERN HIGHWAY, BLAXLAND. 2774
Phone: 0414413627
Birthdate: 27/01/1963 Sex: M Medicare Number: 3227614217
Your Reference: 00026438 Lab Reference: 851503329-C-Biochemistry
Laboratory: Douglass Hanly Moir Pathology
Addressee: DR WEI Z LU Referred by: DR WEI Z LU

Name of Test: Biochemistry
Requested: 07/05/2024 Collected: 08/05/2024 Reported: 08/05/2024 16:20

Clinical notes: FH OF PROSTATE CANCER AND DMII AND ? UNCTROLLED HT , BP 153/92, 148/95
CRESTOR

Clinical Notes : FH OF PROSTATE CANCER AND DMII AND ?
UNCTROLLED HT , BP 153/92, 148/95 PT RX
CRESTOR

Biochemistry

Status	Fasting		
Sodium	140	mmol/L	(135 - 145)
Potassium	4.3	mmol/L	(3.5 - 5.5)
Chloride	105	mmol/L	(95 - 110)
Bicarbonate	28	mmol/L	(20 - 32)
Urea	5.6	mmol/L	(3.5 - 9.0)
Creatinine	80	umol/L	(60 - 110)
eGFR	90	mL/min/1.73m2	(>59)
Urate	0.46	mmol/L	(0.20 - 0.50)
Calcium	2.40	mmol/L	(2.15 - 2.55)
Corrected Calcium	2.26	mmol/L	(2.15 - 2.55)
Magnesium	0.88	mmol/L	(0.65 - 1.00)
Phosphate	1.04	mmol/L	(0.8 - 1.5)
Total Bilirubin	H 26	umol/L	(4 - 20)
Alk Phos	64	U/L	(35 - 110)
Gamma GT	37	U/L	(5 - 50)
LDH	199	U/L	(120 - 250)
AST	28	U/L	(10 - 40)
ALT	33	U/L	(5 - 40)
Total Protein	74	g/L	(64 - 83)
Albumin	H 50	g/L	(36 - 47)
Globulin	24	g/L	(23 - 39)
Cholesterol	4.2	mmol/L	(<5.5)
Triglycerides	0.8	mmol/L	(<2.0)

Comment on Lab ID 851503329

GFR (mL/min/1.73m2) calculated by CKD-EPI formula - see www.kidney.org.au

posure.

NATA Accreditation No 2178

Tests Completed: B12(s), Fol(s), LFT(s), C(s), UCreat(s), E(s), Glu(p),
Phos(s), UA(s), Lipids HDL(s), Ca(s), CRP(s), Mg(s),
RU-Malb, Vit D(s), TSH(s), Active B12(s), HbA1c Mon(e)
Tests Pending : PSA(s), MSU
Sample Pending : BP Monitor

CARFAX-FOSTER, MARE HENRY
131 GREAT WESTERN HIGHWAY, BLAXLAND. 2774
Phone: 0414413627
Birthdate: 27/01/1963 Sex: M Medicare Number: 3227614217
Your Reference: 00026438 Lab Reference: 851503329-E-Vitamin B12/Folate
Laboratory: Douglass Hanly Moir Pathology
Addressee: DR WEI Z LU Referred by: DR WEI Z LU

Name of Test: B12/Folate/RCF
Requested: 07/05/2024 Collected: 08/05/2024 Reported: 09/05/2024 05:50

Clinical notes: FH OF PROSTATE CANCER AND DMII AND ? UNCTROLLED HT , BP 153/92, 148/95 PT RX
CRESTOR

Clinical Notes : FH OF PROSTATE CANCER AND DMII AND ?
UNCTROLLED HT , BP 153/92, 148/95 PT RX
CRESTOR

Vitamin B12 and Folate

Vitamin B12	289	pmol/L	(135 - 650)
Active B12	92	pmol/L	(>35)
Serum Folate	30.7	nmol/L	(>7.0)

Comment on Lab ID 851503329

From 27 November 2023, active B12 (holotranscobalamin) testing will be performed on all patients with low or equivocal (at or below 400 pmol/L) total B12 results. Both tests are eligible for a Medicare rebate under these circumstances.

NATA Accreditation No 2178

Tests Completed: B12(s), Fol(s), LFT(s), C(s), UCreat(s), E(s), Glu(p),
Phos(s), UA(s), Lipids HDL(s), Ca(s), CRP(s), Mg(s),
RU-Malb, Vit D(s), TSH(s), Active B12(s), HbA1c Mon(e)
Tests Pending : PSA(s), MSU
Sample Pending : BP Monitor

CARFAX-FOSTER, MARE HENRY
131 GREAT WESTERN HIGHWAY, BLAXLAND. 2774
Phone: 0414413627
Birthdate: 27/01/1963 Sex: M Medicare Number: 3227614217
Your Reference: 00026438 Lab Reference: 851503329-E-PSA
Laboratory: Douglass Hanly Moir Pathology
Addressee: DR WEI Z LU Referred by: DR WEI Z LU

Name of Test: PSA (Abbott Method)
Requested: 07/05/2024 Collected: 08/05/2024 Reported: 09/05/2024 06:50

Clinical notes: FH OF PROSTATE CANCER AND DMII AND ? UNCTROLLED HT , BP 153/92, 148/9
CRESTOR

Clinical Notes : FH OF PROSTATE CANCER AND DMII AND ?
UNCTROLLED HT , BP 153/92, 148/95 PT RX
CRESTOR

Sample Pending : BP Monitor

CARFAX-FOSTER, MARE HENRY
 131 GREAT WESTERN HIGHWAY, BLAXLAND. 2774
 Phone: 0414413627
 Birthdate: 27/01/1963 Sex: M Medicare Number: 3227614217
 Your Reference: 00026438 Lab Reference: 851503329-E-Thyroid Function
 Laboratory: Douglass Hanly Moir Pathology
 Addressee: DR WEI Z LU Referred by: DR WEI Z LU

Name of Test: Thyroid Function
 Requested: 07/05/2024 Collected: 08/05/2024 Reported: 09/05/2024 04:20

Clinical notes: FH OF PROSTATE CANCER AND DMII AND ? UNCTROLLED HT , BP 153/92, 148/95 PT RX
 CRESTOR

Clinical Notes : FH OF PROSTATE CANCER AND DMII AND ?
 UNCTROLLED HT , BP 153/92, 148/95 PT RX
 CRESTOR

Thyroid Function

TSH
 Comment on Lab ID 851503329 0.97 mIU/L (0.40 - 4.00)

NATA Accreditation No 2178

Tests Completed: B12(s), Fol(s), LFT(s), C(s), UCreat(s), E(s), Glu(p),
 Phos(s), UA(s), Lipids HDL(s), Ca(s), CRP(s), Mg(s),
 RU-Malb, TSH(s), HbA1c Mon(e)
 Tests Pending : Vit D(s), PSA(s), Active B12(s), MSU
 Sample Pending : BP Monitor

CARFAX-FOSTER, MARE HENRY
 131 GREAT WESTERN HIGHWAY, BLAXLAND. 2774
 Phone: 0414413627
 Birthdate: 27/01/1963 Sex: M Medicare Number: 3227614217
 Your Reference: 00026438 Lab Reference: 851503329-C-VITD
 Laboratory: Douglass Hanly Moir Pathology
 Addressee: DR WEI Z LU Referred by: DR WEI Z LU

Name of Test: Vit D(s)
 Requested: 07/05/2024 Collected: 08/05/2024 Reported: 09/05/2024 05:20

Clinical notes: FH OF PROSTATE CANCER AND DMII AND ? UNCTROLLED HT , BP 153/92, 148/95 PT RX
 CRESTOR

Clinical Notes : FH OF PROSTATE CANCER AND DMII AND ?
 UNCTROLLED HT , BP 153/92, 148/95 PT RX
 CRESTOR

25-OH Vitamin D

Vitamin D 74 nmol/L (50 - 140)
 Comment on Lab ID 851503329

According to the Position Statement 'Vitamin D and health in adults in Australia and New Zealand' MJA, 196(11):686-687, 2012, Vitamin D status is defined as:

Mild Deficiency	30	-	49 nmol/L
Moderate Deficiency	12.5	-	29 nmol/L
Severe Deficiency	<12.5		nmol/L

Vitamin D adequacy can be defined as a level >49 nmol/L at the end of
 level may need to be 10 - 20 nmol/L higher at the end of

Cardiovascular disease risk please see www.cvdcheck.org.au

The above decision limits are based on the European Atherosclerosis Society (EAS) and European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Consensus Statement 2016 and the Australasian Association of Clinical Biochemistry and Laboratory Medicine (AACB) Lipid Reporting Guideline 2018.

Lipid treatment targets for patients at high risk of cardiovascular disease:

Total cholesterol	<4.0 mmol/L
Triglyceride	<2.0 mmol/L
HDL cholesterol	>1.0 mmol/L
LDL cholesterol	<2.5 mmol/L (<1.8 mmol/L for very high risk)
Non-HDL cholesterol	<3.3 mmol/L (<2.5 mmol/L for very high risk)

High risk - Primary prevention

Very high risk - Secondary prevention

Target values from the AACB Lipid Reporting Guideline 2018.

please note that as there is a continuum of risk, benefits are obtained for any measured lipid components moving towards and beyond the various target levels.

NATA Accreditation No 2178

Tests Completed: LFT(s), C(s), UCreat(s), E(s), Glu(p), Phos(s), UA(s),
Lipids HDL(s), Ca(s), CRP(s), Mg(s)

Tests Pending : B12(s), FOL(s), RU-Malb, Vit D(s), TSH(s), PSA(s),
HbA1c Mon(e), MSU

Sample Pending : BP Monitor

CARFAX-FOSTER, MARE HENRY
131 GREAT WESTERN HIGHWAY, BLAXLAND. 2774
Phone: 0414413627
Birthdate: 27/01/1963 Sex: M Medicare Number: 3227614217
Your Reference: 00026438 Lab Reference: 851503329-C-CRP
Laboratory: Douglass Hanly Moir Pathology
Addressee: DR WEI Z LU Referred by: DR WEI Z LU

Name of Test: CRP(s)

Requested: 07/05/2024 Collected: 08/05/2024 Reported: 08/05/2024 16:20

Clinical notes: FH OF PROSTATE CANCER AND DMII AND ? UNCTROLLED HT , BP 153/92, 148/95
CRESTOR

Clinical Notes : FH OF PROSTATE CANCER AND DMII AND ?
UNCTROLLED HT , BP 153/92, 148/95 PT RX
CRESTOR

C Reactive Protein (High Sens)

CRP 0.5 mg/L (0.0 - 5.0)
Comment on Lab ID 851503329

NATA Accreditation No 2178

Tests Completed: LFT(s), C(s), UCreat(s), E(s), Glu(p), Phos(s), UA(s),
Lipids HDL(s), Ca(s), CRP(s), Mg(s)

Tests Pending : B12(s), FOL(s), RU-Malb, Vit D(s), TSH(s), PSA(s),
HbA1c Mon(e), MSU

Sample Pending : BP Monitor

Your Reference: 00026438 Lab Reference: 851503329-C-MALBUR
Laboratory: Douglass Hanly Moir Pathology
Addressee: DR WEI Z LU Referred by: DR WEI Z LU
Name of Test: RU-Malb
Requested: 07/05/2024 Collected: 08/05/2024 Reported: 08/05/2024 22:20
Clinical notes: FH OF PROSTATE CANCER AND DMII AND ? UNCTROLLED HT , BP 153/92, 148/95 PT RX
CRESTOR

Clinical Notes : FH OF PROSTATE CANCER AND DMII AND ?
UNCTROLLED HT , BP 153/92, 148/95 PT RX
CRESTOR

Microalbumin, Random Urine

U-Creatinine	13.2	mmol/L	
R U-Albumin	16.6	mg/L	
R U-Albumin/Creat	1.3	mg/mmol	(<2.5)

NATA Accreditation No 2178

Tests Completed: LFT(s), C(s), UCreat(s), E(s), Glu(p), Phos(s), UA(s),
Lipids HDL(s), Ca(s), CRP(s), Mg(s), RU-Malb
Tests Pending : B12(s), Fol(s), Vit D(s), TSH(s), PSA(s), HbA1c Mon(e), MSU
Sample Pending : BP Monitor

CARFAX-FOSTER, MARE HENRY
131 GREAT WESTERN HIGHWAY, BLAXLAND. 2774
Phone: 0414413627
Birthdate: 27/01/1963 Sex: M Medicare Number: 3227614217
Your Reference: 00026438 Lab Reference: 851503329-C-GHB
Laboratory: Douglass Hanly Moir Pathology
Addressee: DR WEI Z LU Referred by: DR WEI Z LU

Name of Test: HbA1c
Requested: 07/05/2024 Collected: 08/05/2024 Reported: 09/05/2024 01:20

Clinical notes: FH OF PROSTATE CANCER AND DMII AND ? UNCTROLLED HT , BP 153/92, 148/95 PT RX
CRESTOR

Clinical Notes : FH OF PROSTATE CANCER AND DMII AND ?
UNCTROLLED HT , BP 153/92, 148/95 PT RX
CRESTOR

Haemoglobin A1c

HbA1c (IFCC)	H 46	mmol/mol	(20 - 38)
HbA1c (NGSP)	H 6.4	%	(4.0 - 5.6)

Comment on Lab ID 851503329

HbA1c TARGET LEVELS (mmol/mol) for adults with diabetes mellitus (DM)*
<43 (<6.1%) recent type 2 DM either in pregnancy/planning pregnancy
or requiring lifestyle modification +/- metformin
<49 (<6.6%) recent type 2 DM requiring treatment other than
metformin or insulin
<54 (<7.1%) GENERAL TARGET for type 1 DM including pregnancy/planning
pregnancy and type 2 DM of long duration or with clinical
cardiovascular disease (any therapy) or requiring insulin
65 (<8.1%) type 1 or type 2 DM associated with recurrent
severe hypoglycaemia or hypoglycaemia unawareness
Position Statement of the Australian Diabetes Society
MJA 2009;191(6):339-346.

TA Accreditation No 2178

THRELFALL, HEATHER
 2/4 CROSS ST, GLENBROOK. 2773
 Phone: 0414892703
 Birthdate: 29/08/1953 Sex: F Medicare Number: 2245815431
 Your Reference: A169DFDEF7 Lab Reference: 835774111-C-C205
 Laboratory: bsp
 Addressee: DR SANAA LABIB Referred by: DR SANAA LABIB

Name of Test: Lipids HDL(s)
 Requested: 10/05/2023 Collected: 17/08/2023 Reported: 17/08/2023 09:43

Clinical notes: NO HISTORY

Clinical Notes : NO HISTORY

Date	04/12/20	16/12/21	28/07/22	17/08/23		
Time F-Fast	0832 F	0615 F	0635 F	0645 F		
Lab ID	848509029	865862925	882146112	835774111	Units	Reference
Status	Fasting	Fasting	Fasting	Fasting		
Cholesterol	H 6.3	H 6.9	H 6.6	H 6.1	mmol/L	(<5.5)
Triglycerides	0.9	0.8	0.9	0.8	mmol/L	(<2.0)
HDL Chol.	2.1	H 2.4	H 2.2	2.1	mmol/L	(>1.2)
LDL Chol.	H 3.8	H 4.1	H 4.0	H 3.6	mmol/L	(<3.0)
Non-HDL Chol.				H 4.0	mmol/L	(<4.0)

Comments on Collection 17/08/23 0645 F:
 Please note that the above reference limits are decision limits.
 A flag based on these limits is an indication to review the absolute
 cardiovascular risk for the patient. For assessment of absolute
 cardiovascular disease risk please see www.cvdcheck.org.au

The above decision limits are based on the European Atherosclerosis Society
 (EAS) and European Federation of Clinical Chemistry and Laboratory Medicine
 (EFLM) Consensus Statement 2016 and the Australasian Association of
 Clinical Biochemistry and Laboratory Medicine (AACB) Lipid Reporting
 Guideline 2018.

Lipid treatment targets for patients at high risk of cardiovascular
 disease:

Total cholesterol	<4.0 mmol/L
Triglyceride	<2.0 mmol/L
HDL cholesterol	>1.0 mmol/L
LDL cholesterol	<2.5 mmol/L (<1.8 mmol/L for very high risk)
Non-HDL cholesterol	<3.3 mmol/L (<2.5 mmol/L for very high risk)

High risk - Primary prevention Very high risk - Secondary prevention

Target values from the AACB Lipid Reporting Guideline 2018.

Please note that as there is a continuum of risk, benefits are obtained for
 any measured lipid components moving towards and beyond the various target
 levels.

TA Accreditation No 2178

Your Reference: 00026438 Lab Reference: 851503329-C-MALBUR
Laboratory: Douglass Hanly Moir Pathology
Addressee: DR WEI Z LU Referred by: DR WEI Z LU

Name of Test: RU-Malb
Requested: 07/05/2024 Collected: 08/05/2024 Reported: 08/05/2024 22:20

Clinical notes: FH OF PROSTATE CANCER AND DMII AND ? UNCTROLLED HT , BP 153/92, 148/95 PT RX
CRESTOR

Clinical Notes : FH OF PROSTATE CANCER AND DMII AND ?
UNCTROLLED HT , BP 153/92, 148/95 PT RX
CRESTOR

Microalbumin, Random Urine

U-Creatinine	13.2	mmol/L	
R U-Albumin	16.6	mg/L	
R U-Albumin/Creat	1.3	mg/mmol	(<2.5)

NATA Accreditation No 2178

Tests Completed: LFT(s), C(s), UCreat(s), E(s), Glu(p), Phos(s), UA(s),
Lipids HDL(s), Ca(s), CRP(s), Mg(s), RU-Malb

Tests Pending : B12(s), Fol(s), Vit D(s), TSH(s), PSA(s), HbA1c Mon(e), MSU
Sample Pending : BP Monitor

CARFAX-FOSTER, MARE HENRY
131 GREAT WESTERN HIGHWAY, BLAXLAND. 2774
Phone: 0414413627
Birthdate: 27/01/1963 Sex: M Medicare Number: 3227614217
Your Reference: 00026438 Lab Reference: 851503329-C-GHB
Laboratory: Douglass Hanly Moir Pathology
Addressee: DR WEI Z LU Referred by: DR WEI Z LU

Name of Test: HbA1c
Requested: 07/05/2024 Collected: 08/05/2024 Reported: 09/05/2024 01:20

Clinical notes: FH OF PROSTATE CANCER AND DMII AND ? UNCTROLLED HT , BP 153/92, 148/95 PT RX
CRESTOR

Clinical Notes : FH OF PROSTATE CANCER AND DMII AND ?
UNCTROLLED HT , BP 153/92, 148/95 PT RX
CRESTOR

Haemoglobin A1c

HbA1c (IFCC)	H 46	mmol/mol	(20 - 38)
HbA1c (NGSP)	H 6.4	%	(4.0 - 5.6)

Comment on Lab ID 851503329

HbA1c TARGET LEVELS (mmol/mol) for adults with diabetes mellitus (DM)*
<43 (<6.1%) recent type 2 DM either in pregnancy/planning pregnancy
or requiring lifestyle modification +/- metformin
<49 (<6.6%) recent type 2 DM requiring treatment other than
metformin or insulin
<54 (<7.1%) GENERAL TARGET for type 1 DM including pregnancy/planning
pregnancy and type 2 DM of long duration or with clinical
cardiovascular disease (any therapy) or requiring insulin
65 (<8.1%) type 1 or type 2 DM associated with recurrent
severe hypoglycaemia or hypoglycaemia unawareness

Position Statement of the Australian Diabetes Society
MJA 2009;191(6):339-346.

NATA Accreditation No 2178